PAX3 Waardenburg Spectrum

Genetic MONDO:0018094 Pathograph 6 Waardenburg Syndrome Pigmentary Disorder Sensorineural Hearing Loss

PAX3 Waardenburg spectrum is an auditory-pigmentary neural crest disorder caused by pathogenic variants in PAX3, a paired-box transcription factor. Heterozygous PAX3 variants classically cause Waardenburg syndrome type 1, with sensorineural hearing loss, pigmentary disturbance, and dystopia canthorum, and can also cause Klein-Waardenburg syndrome/type 3 with musculoskeletal involvement. The shared mechanism is dosage-sensitive or DNA-binding PAX3 dysfunction that disrupts downstream melanocyte regulatory programs, including MITF activation with SOX10, reducing melanoblast and cochlear melanocyte development. Craniofacial-deafness-hand syndrome is an allelic PAX3 condition with overlapping deafness and craniofacial features but is treated here as a related differential rather than a Waardenburg subtype.

Ask OpenScientist

Ask a research question about PAX3 Waardenburg Spectrum. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

2
Inheritance
5
Pathophys.
5
Phenotypes
6
Pathograph
1
Genes
2
Subtypes
1
Differentials
1
References
1
Deep Research
👪

Inheritance

2
Autosomal dominant inheritance HP:0000006
Most PAX3 Waardenburg presentations are heterozygous autosomal dominant disorders with variable expressivity and incomplete penetrance for hearing loss and pigmentary findings.
Autosomal dominant inheritance Penetrance: INCOMPLETE
Semidominant dosage-sensitive inheritance HP:0032113
The entry records a dosage-sensitive spectrum because PAX3 pathogenic variants include monoallelic WS1/WS3 alleles and more severe allelic presentations. The primary ClinGen assertion remains autosomal dominant.
Semidominant inheritance
◆

Subtypes

2
Waardenburg Syndrome Type 1 MONDO:0008670
The classic PAX3-associated form, characterized by sensorineural hearing loss, dystopia canthorum, and pigmentary abnormalities.
Show evidence (1 reference)
PMID:8447316 SUPPORT Human Clinical
"Waardenburg syndrome type I (WS-I) is an autosomal dominant disorder characterized by sensorineural hearing loss, dystopia canthorum, pigmentary disturbances, and other developmental defects."
Defines the WS1 phenotype and links it to PAX3 mutations in the same report.
Waardenburg Syndrome Type 3 MONDO:0007862
A PAX3-related Waardenburg form with WS1-like auditory-pigmentary findings plus musculoskeletal abnormalities.
Show evidence (1 reference)
PMID:8447316 SUPPORT Human Clinical
"Klein-Waardenburg syndrome (WS-III) is a disorder with many of the same characteristics as WS-I and includes musculoskeletal abnormalities."
Establishes WS3/Klein-Waardenburg as a PAX3-associated extension of WS1 with musculoskeletal involvement.
⚙

Pathophysiology

5
PAX3 transcription factor dysfunction
Pathogenic PAX3 variants disrupt a paired-box transcription factor required for embryonic neural crest development. Loss-of-function alleles reduce PAX3 dosage, while paired-domain and homeodomain missense variants can impair DNA binding and target-gene regulation.
migratory neural crest cell link
PAX3 link
neural crest cell migration link ⚠ ABNORMAL
Downstream
Reduced PAX3-SOX10-MITF melanocyte transcriptional program PAX3 cooperates with SOX10 to activate MITF expression in melanocyte lineage cells.
Show evidence (2 references)
PMID:1347148 SUPPORT Human Clinical
"Waardenburg's syndrome (WS) is an autosomal dominant combination of deafness and pigmentary disturbances, probably caused by defective function of the embryonic neural crest."
Establishes the neural crest model for Waardenburg syndrome in the PAX3 discovery report.
PMID:8447316 SUPPORT Human Clinical
"PAX3 is a DNA-binding protein that contains a structural motif known as the paired domain and is believed to regulate the expression of other genes."
Links disease-associated PAX3 variants to disrupted transcriptional regulation.
Reduced PAX3-SOX10-MITF melanocyte transcriptional program
PAX3 and SOX10 normally cooperate upstream of MITF, the central melanocyte lineage transcription factor. PAX3 dysfunction reduces this regulatory hierarchy and impairs melanocyte differentiation and survival.
melanoblast link
PAX3 link MITF link
melanocyte differentiation link ↓ DECREASED
Downstream
Melanoblast and melanocyte developmental deficiency Reduced melanocyte lineage transcription impairs melanoblast and melanocyte development.
Show evidence (1 reference)
PMID:10982026 SUPPORT In Vitro
"We show that SOX10 is capable of transactivating the MITF promoter 100-fold, and that this transactivation is further stimulated by PAX3."
Supports the PAX3/SOX10/MITF transcriptional hierarchy used as the shared melanocyte mechanism.
Melanoblast and melanocyte developmental deficiency
Impaired PAX3-dependent melanocyte lineage development reduces melanoblasts and melanocytes in skin, hair, iris, and cochlear structures.
melanoblast link melanocyte link
developmental pigmentation link ↓ DECREASED
Downstream
Stria vascularis melanocyte deficiency Cochlear melanocyte deficiency disrupts endocochlear potential generation and contributes to hearing impairment.
Cutaneous hair and iris melanocyte deficiency Melanocyte deficiency in pigmentary tissues causes white forelock, hypopigmented patches, and iris pigment anomalies.
Show evidence (1 reference)
PMID:38278860 SUPPORT Model Organism
"these results suggest that Pax3 is required for the development of neural crest cell-derived cochlear melanocytes, whose absence may contribute to congenital hearing loss of Waardenburg syndrome in humans."
Model-organism evidence links PAX3 deficiency to loss of neural crest-derived cochlear melanocytes.
Stria vascularis melanocyte deficiency
Reduced PAX3-dependent cochlear melanocytes in the stria vascularis impair the melanocyte/intermediate-cell contribution required for normal auditory function.
melanocyte link
stria vascularis link
Show evidence (1 reference)
PMID:38278860 SUPPORT Model Organism
"Cochlear melanocytes are intermediate cells in the stria vascularis that generate endocochlear potentials required for auditory function."
Establishes the cochlear melanocyte mechanism that links PAX3-dependent melanocyte development to hearing.
Cutaneous hair and iris melanocyte deficiency
Melanocyte deficiency in hair follicles, skin, and iris produces the visible pigmentary findings of PAX3 Waardenburg syndrome.
melanocyte link
pigmentation link ↓ DECREASED
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for PAX3 Waardenburg Spectrum Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

5
Ear 1
Sensorineural hearing impairment FREQUENT Sensorineural hearing impairment (HP:0000407)
Show evidence (1 reference)
PMID:8447316 SUPPORT Human Clinical
"Waardenburg syndrome type I (WS-I) is an autosomal dominant disorder characterized by sensorineural hearing loss, dystopia canthorum, pigmentary disturbances, and other developmental defects."
Sensorineural hearing loss is a defining clinical feature of PAX3-related WS1.
Eye 1
Heterochromia iridis FREQUENT Heterochromia iridis (HP:0001100)
Integument 1
White forelock FREQUENT White forelock (HP:0002211)
Other 2
Dystopia canthorum FREQUENT
Show evidence (1 reference)
PMID:8447316 SUPPORT Human Clinical
"Waardenburg syndrome type I (WS-I) is an autosomal dominant disorder characterized by sensorineural hearing loss, dystopia canthorum, pigmentary disturbances, and other developmental defects."
The PAX3 WS1 report explicitly includes dystopia canthorum in the phenotype.
Musculoskeletal abnormalities FREQUENT
Show evidence (1 reference)
PMID:8447316 SUPPORT Human Clinical
"Klein-Waardenburg syndrome (WS-III) is a disorder with many of the same characteristics as WS-I and includes musculoskeletal abnormalities."
The quoted report establishes musculoskeletal findings as part of the WS3 PAX3 phenotype.
🧬

Genetic Associations

1
PAX3 (Causative)
Show evidence (2 references)
PMID:1347149 SUPPORT Human Clinical
"The mutation was found in the HuP2 gene, a member of the paired domain family of proteins that bind DNA and regulate gene expression."
Identifies a paired-domain gene mutation causing Waardenburg syndrome in a segregating family.
PMID:8447316 SUPPORT Human Clinical
"The results indicate that mutations in the PAX3 gene can cause both WS-I and WS-III."
Establishes PAX3 as causal for both classic WS1 and WS3.
🔀

Differential Diagnoses

1

Conditions with similar clinical presentations that must be differentiated from PAX3 Waardenburg Spectrum:

Craniofacial-deafness-hand syndrome Not Yet Curated MONDO:0007395
Overlapping Features A PAX3 allelic condition caused by paired-domain missense variants. It overlaps through deafness and craniofacial anomalies but has a distinct hand phenotype and should not be modeled as a Waardenburg subtype.
Show evidence (1 reference)
PMID:8664898 SUPPORT Human Clinical
"Craniofacial-deafness-hand syndrome (MIM 122880) is inherited as an autosomal dominant mutation characterized by the absence or hypoplasia of the nasal bones, profound sensorineural deafness"
Establishes CDHS as a distinct autosomal dominant PAX3 allelic condition with profound deafness and craniofacial-hand features.
{ }

Source YAML

click to show 
name: PAX3 Waardenburg Spectrum
creation_date: '2026-05-28T00:00:00Z'
description: >-
  PAX3 Waardenburg spectrum is an auditory-pigmentary neural crest disorder
  caused by pathogenic variants in PAX3, a paired-box transcription factor.
  Heterozygous PAX3 variants classically cause Waardenburg syndrome type 1,
  with sensorineural hearing loss, pigmentary disturbance, and dystopia
  canthorum, and can also cause Klein-Waardenburg syndrome/type 3 with
  musculoskeletal involvement. The shared mechanism is dosage-sensitive or
  DNA-binding PAX3 dysfunction that disrupts downstream melanocyte regulatory
  programs, including MITF activation with SOX10, reducing melanoblast and
  cochlear melanocyte development. Craniofacial-deafness-hand syndrome is an
  allelic PAX3 condition with overlapping deafness and craniofacial features but
  is treated here as a related differential rather than a Waardenburg subtype.
category: Genetic
parents:
- Waardenburg Syndrome
- Pigmentary Disorder
- Sensorineural Hearing Loss
disease_term:
  preferred_term: Waardenburg syndrome
  term:
    id: MONDO:0018094
    label: Waardenburg syndrome
tracked_issues:
- url: https://github.com/monarch-initiative/dismech/issues/3309
  title: Curate Waardenburg syndrome as gene-axis mechanism spectra
  tracked_issue_role: curation_followup
  tracked_issue_status: OPEN
  notes: >-
    Issue 3309 requested gene-axis modeling for PAX3, SOX10, and EDN3/EDNRB
    Waardenburg mechanisms.
external_assertions:
- name: ClinGen PAX3 Waardenburg syndrome validity assertion
  source: ClinGen
  assertion_type: gene_disease_validity
  external_id: CGGV:assertion_594ef026-3730-43bc-b721-d15cf0bbbf26-2017-11-15T050000.000Z
  url: https://search.clinicalgenome.org/kb/gene-validity/CGGV:assertion_594ef026-3730-43bc-b721-d15cf0bbbf26-2017-11-15T050000.000Z
  description: >-
    ClinGen Hearing Loss Gene Curation Expert Panel assertion classifying PAX3
    and autosomal dominant Waardenburg syndrome as Definitive.
  evidence:
  - reference: CGGV:assertion_594ef026-3730-43bc-b721-d15cf0bbbf26-2017-11-15T050000.000Z
    reference_title: PAX3 / Waardenburg syndrome (Definitive)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      In summary, PAX3 is definitively associated with autosomal dominant Waardenberg syndrome.
    explanation: >-
      ClinGen provides the structured gene-disease validity assertion aligned to
      the broad PAX3 Waardenburg spectrum modeled here.
has_subtypes:
- name: Waardenburg Syndrome Type 1
  display_name: Waardenburg Syndrome Type 1
  subtype_term:
    preferred_term: Waardenburg syndrome type 1
    term:
      id: MONDO:0008670
      label: Waardenburg syndrome type 1
  description: >-
    The classic PAX3-associated form, characterized by sensorineural hearing
    loss, dystopia canthorum, and pigmentary abnormalities.
  evidence:
  - reference: PMID:8447316
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Waardenburg syndrome type I (WS-I) is an autosomal dominant disorder characterized by sensorineural hearing loss, dystopia canthorum, pigmentary disturbances, and other developmental defects.
    explanation: >-
      Defines the WS1 phenotype and links it to PAX3 mutations in the same
      report.
- name: Klein-Waardenburg Syndrome
  display_name: Waardenburg Syndrome Type 3
  subtype_term:
    preferred_term: Waardenburg syndrome type 3
    term:
      id: MONDO:0007862
      label: Waardenburg syndrome type 3
  description: >-
    A PAX3-related Waardenburg form with WS1-like auditory-pigmentary findings
    plus musculoskeletal abnormalities.
  evidence:
  - reference: PMID:8447316
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Klein-Waardenburg syndrome (WS-III) is a disorder with many of the same characteristics as WS-I and includes musculoskeletal abnormalities.
    explanation: >-
      Establishes WS3/Klein-Waardenburg as a PAX3-associated extension of WS1
      with musculoskeletal involvement.
inheritance:
- name: Autosomal dominant inheritance
  inheritance_term:
    preferred_term: Autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  penetrance: INCOMPLETE
  description: >-
    Most PAX3 Waardenburg presentations are heterozygous autosomal dominant
    disorders with variable expressivity and incomplete penetrance for hearing
    loss and pigmentary findings.
- name: Semidominant dosage-sensitive inheritance
  inheritance_term:
    preferred_term: Semidominant inheritance
    term:
      id: HP:0032113
      label: Semidominant inheritance
  description: >-
    The entry records a dosage-sensitive spectrum because PAX3 pathogenic
    variants include monoallelic WS1/WS3 alleles and more severe allelic
    presentations. The primary ClinGen assertion remains autosomal dominant.
phenotypes:
- category: Audiological
  name: Sensorineural hearing impairment
  frequency: FREQUENT
  description: >-
    Congenital or early-onset sensorineural hearing impairment reflects abnormal
    development or maintenance of neural crest-derived cochlear melanocytes in
    the stria vascularis.
  phenotype_term:
    preferred_term: Sensorineural hearing impairment
    term:
      id: HP:0000407
      label: Sensorineural hearing impairment
  evidence:
  - reference: PMID:8447316
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Waardenburg syndrome type I (WS-I) is an autosomal dominant disorder characterized by sensorineural hearing loss, dystopia canthorum, pigmentary disturbances, and other developmental defects.
    explanation: >-
      Sensorineural hearing loss is a defining clinical feature of PAX3-related
      WS1.
- category: Dermatologic
  name: White forelock
  frequency: FREQUENT
  description: >-
    White forelock or patchy depigmentation reflects melanocyte developmental
    deficiency in hair follicles and skin.
  phenotype_term:
    preferred_term: White forelock
    term:
      id: HP:0002211
      label: White forelock
- category: Ophthalmologic
  name: Heterochromia iridis
  frequency: FREQUENT
  description: >-
    Iris pigment asymmetry reflects abnormal melanocyte development in the
    ocular pigmentary component of the Waardenburg spectrum.
  phenotype_term:
    preferred_term: Heterochromia iridis
    term:
      id: HP:0001100
      label: Heterochromia iridis
- category: Craniofacial
  name: Dystopia canthorum
  frequency: FREQUENT
  description: >-
    Lateral displacement of the inner canthi is a characteristic WS1 feature and
    helps distinguish many PAX3 cases from WS2.
  evidence:
  - reference: PMID:8447316
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Waardenburg syndrome type I (WS-I) is an autosomal dominant disorder characterized by sensorineural hearing loss, dystopia canthorum, pigmentary disturbances, and other developmental defects.
    explanation: >-
      The PAX3 WS1 report explicitly includes dystopia canthorum in the
      phenotype.
- category: Musculoskeletal
  name: Musculoskeletal abnormalities
  subtype: Klein-Waardenburg Syndrome
  frequency: FREQUENT
  description: >-
    Limb or musculoskeletal anomalies distinguish Klein-Waardenburg syndrome
    from classic WS1 within the PAX3 spectrum.
  evidence:
  - reference: PMID:8447316
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Klein-Waardenburg syndrome (WS-III) is a disorder with many of the same characteristics as WS-I and includes musculoskeletal abnormalities.
    explanation: >-
      The quoted report establishes musculoskeletal findings as part of the WS3
      PAX3 phenotype.
pathophysiology:
- name: PAX3 transcription factor dysfunction
  description: >-
    Pathogenic PAX3 variants disrupt a paired-box transcription factor required
    for embryonic neural crest development. Loss-of-function alleles reduce PAX3
    dosage, while paired-domain and homeodomain missense variants can impair DNA
    binding and target-gene regulation.
  genes:
  - preferred_term: PAX3
    term:
      id: hgnc:8617
      label: PAX3
  cell_types:
  - preferred_term: migratory neural crest cell
    term:
      id: CL:0000333
      label: migratory neural crest cell
  biological_processes:
  - preferred_term: neural crest cell migration
    term:
      id: GO:0001755
      label: neural crest cell migration
    modifier: ABNORMAL
  evidence:
  - reference: PMID:1347148
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Waardenburg's syndrome (WS) is an autosomal dominant combination of deafness and pigmentary disturbances, probably caused by defective function of the embryonic neural crest.
    explanation: >-
      Establishes the neural crest model for Waardenburg syndrome in the PAX3
      discovery report.
  - reference: PMID:8447316
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      PAX3 is a DNA-binding protein that contains a structural motif known as the paired domain and is believed to regulate the expression of other genes.
    explanation: >-
      Links disease-associated PAX3 variants to disrupted transcriptional
      regulation.
  downstream:
  - target: Reduced PAX3-SOX10-MITF melanocyte transcriptional program
    description: >-
      PAX3 cooperates with SOX10 to activate MITF expression in melanocyte
      lineage cells.
- name: Reduced PAX3-SOX10-MITF melanocyte transcriptional program
  conforms_to: "neural_crest_melanocyte_deficiency#Neural Crest Melanocyte Program Disruption"
  description: >-
    PAX3 and SOX10 normally cooperate upstream of MITF, the central melanocyte
    lineage transcription factor. PAX3 dysfunction reduces this regulatory
    hierarchy and impairs melanocyte differentiation and survival.
  genes:
  - preferred_term: PAX3
    term:
      id: hgnc:8617
      label: PAX3
  - preferred_term: MITF
    term:
      id: hgnc:7105
      label: MITF
  cell_types:
  - preferred_term: melanoblast
    term:
      id: CL:0000541
      label: melanoblast
  biological_processes:
  - preferred_term: melanocyte differentiation
    term:
      id: GO:0030318
      label: melanocyte differentiation
    modifier: DECREASED
  evidence:
  - reference: PMID:10982026
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      We show that SOX10 is capable of transactivating the MITF promoter 100-fold, and that this transactivation is further stimulated by PAX3.
    explanation: >-
      Supports the PAX3/SOX10/MITF transcriptional hierarchy used as the shared
      melanocyte mechanism.
  downstream:
  - target: Melanoblast and melanocyte developmental deficiency
    description: >-
      Reduced melanocyte lineage transcription impairs melanoblast and
      melanocyte development.
- name: Melanoblast and melanocyte developmental deficiency
  conforms_to: "neural_crest_melanocyte_deficiency#Melanoblast Migration and Survival Defect"
  description: >-
    Impaired PAX3-dependent melanocyte lineage development reduces melanoblasts
    and melanocytes in skin, hair, iris, and cochlear structures.
  cell_types:
  - preferred_term: melanoblast
    term:
      id: CL:0000541
      label: melanoblast
  - preferred_term: melanocyte
    term:
      id: CL:0000148
      label: melanocyte
  biological_processes:
  - preferred_term: developmental pigmentation
    term:
      id: GO:0048066
      label: developmental pigmentation
    modifier: DECREASED
  evidence:
  - reference: PMID:38278860
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      these results suggest that Pax3 is required for the development of neural crest cell-derived cochlear melanocytes, whose absence may contribute to congenital hearing loss of Waardenburg syndrome in humans.
    explanation: >-
      Model-organism evidence links PAX3 deficiency to loss of neural
      crest-derived cochlear melanocytes.
  downstream:
  - target: Stria vascularis melanocyte deficiency
    description: >-
      Cochlear melanocyte deficiency disrupts endocochlear potential generation
      and contributes to hearing impairment.
  - target: Cutaneous hair and iris melanocyte deficiency
    description: >-
      Melanocyte deficiency in pigmentary tissues causes white forelock,
      hypopigmented patches, and iris pigment anomalies.
- name: Stria vascularis melanocyte deficiency
  conforms_to: "neural_crest_melanocyte_deficiency#Stria Vascularis Melanocyte Deficiency"
  description: >-
    Reduced PAX3-dependent cochlear melanocytes in the stria vascularis impair
    the melanocyte/intermediate-cell contribution required for normal auditory
    function.
  cell_types:
  - preferred_term: melanocyte
    term:
      id: CL:0000148
      label: melanocyte
  locations:
  - preferred_term: stria vascularis
    term:
      id: UBERON:0002282
      label: stria vascularis of cochlear duct
  evidence:
  - reference: PMID:38278860
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Cochlear melanocytes are intermediate cells in the stria vascularis that generate endocochlear potentials required for auditory function.
    explanation: >-
      Establishes the cochlear melanocyte mechanism that links PAX3-dependent
      melanocyte development to hearing.
- name: Cutaneous hair and iris melanocyte deficiency
  conforms_to: "neural_crest_melanocyte_deficiency#Cutaneous Hair and Iris Melanocyte Deficiency"
  description: >-
    Melanocyte deficiency in hair follicles, skin, and iris produces the visible
    pigmentary findings of PAX3 Waardenburg syndrome.
  cell_types:
  - preferred_term: melanocyte
    term:
      id: CL:0000148
      label: melanocyte
  biological_processes:
  - preferred_term: pigmentation
    term:
      id: GO:0043473
      label: pigmentation
    modifier: DECREASED
genetic:
- name: PAX3
  gene_term:
    preferred_term: PAX3
    term:
      id: hgnc:8617
      label: PAX3
  association: Causative
  features: >-
    Heterozygous pathogenic PAX3 variants cause WS1 and WS3. Variant classes
    include loss-of-function and paired-domain/homeodomain missense variants
    that disrupt DNA binding and transcriptional regulation.
  evidence:
  - reference: PMID:1347149
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The mutation was found in the HuP2 gene, a member of the paired domain family of proteins that bind DNA and regulate gene expression.
    explanation: >-
      Identifies a paired-domain gene mutation causing Waardenburg syndrome in a
      segregating family.
  - reference: PMID:8447316
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The results indicate that mutations in the PAX3 gene can cause both WS-I and WS-III.
    explanation: >-
      Establishes PAX3 as causal for both classic WS1 and WS3.
differential_diagnoses:
- name: Craniofacial-deafness-hand syndrome
  disease_term:
    preferred_term: craniofacial-deafness-hand syndrome
    term:
      id: MONDO:0007395
      label: craniofacial-deafness-hand syndrome
  description: >-
    A PAX3 allelic condition caused by paired-domain missense variants. It
    overlaps through deafness and craniofacial anomalies but has a distinct hand
    phenotype and should not be modeled as a Waardenburg subtype.
  evidence:
  - reference: PMID:8664898
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Craniofacial-deafness-hand syndrome (MIM 122880) is inherited as an autosomal dominant mutation characterized by the absence or hypoplasia of the nasal bones, profound sensorineural deafness
    explanation: >-
      Establishes CDHS as a distinct autosomal dominant PAX3 allelic condition
      with profound deafness and craniofacial-hand features.
notes: >-
  SNAI2 is not modeled as a PAX3-spectrum subtype. Issue 3309 evidence and
  ClinGen classify SNAI2 Waardenburg evidence as limited; it should remain a
  limited-evidence module note unless future independent data justify a separate
  entry.
references:
- reference: PMID:20301703
  title: Waardenburg Syndrome Type I.
  tags:
  - GeneReviews
📚

References & Deep Research

References

1
PMID:20301703
Waardenburg Syndrome Type I.
No top-level findings curated for this source.

Deep Research

1
Falcon ▸
Disease Characteristics Research Template
Edison Scientific Literature 2026-05-28T11:54:33.850850

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

  • Disease Name: PAX3 Waardenburg Spectrum
  • MONDO ID: (if available)
  • Category: Genetic

Research Objectives

Please provide a comprehensive research report on PAX3 Waardenburg Spectrum covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

  • What is the disease? Provide a concise overview.
  • What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
  • What are the common synonyms and alternative names?
  • Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

  • Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
  • Risk Factors:

    Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases

  • Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  • Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
  • Protective Factors:

    Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases

  • Genetic protective factors (protective variants, modifier alleles)
  • Environmental protective factors (diet, lifestyle, exposures that reduce risk)
  • Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

    Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

  • Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

    Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene

  • Pathogenic Variants:
  • Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  • Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  • Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  • Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  • Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
  • Functional consequences (loss of function, gain of function, dominant negative)
  • Modifier Genes: Genes that modify disease severity or expression
  • Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

    Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

  • Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

    Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases

  • Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

    Search first: CDC databases, WHO, PubMed, NHANES

  • Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

    Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

  • Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

    Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc

  • Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

    Search first: Gene Ontology (GO), Reactome, KEGG, PubMed

  • Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

    Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold

  • Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

    Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA

  • Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

    Search first: ImmPort, Immunome Database, IEDB, Gene Ontology

  • Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

    Search first: PubMed, Gene Ontology, Reactome

  • Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

    Search first: BRENDA, UniProt, KEGG, OMIM, PubMed

  • Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Molecular Profiling (if available):
  • Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  • Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  • Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
  • Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  • Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
  • Advanced Technologies (if applicable):
  • Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  • Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
  • Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  • Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

  • Organ Level:
  • Primary organs directly affected
  • Secondary organ involvement (complications, secondary effects)
  • Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

    Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT

  • Tissue and Cell Level:
  • Specific tissue types affected (epithelial, connective, muscle, nervous)
  • Specific cell populations targeted (with Cell Ontology terms)

    Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB

  • Subcellular Level:
  • Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

    Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas

  • Localization:
  • Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
  • Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

  • Onset:
  • Typical age of onset (congenital, pediatric, adult, geriatric)
  • Onset pattern (acute, subacute, chronic, insidious)

    Search first: OMIM, Orphanet, HPO, PubMed

  • Progression:
  • Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
  • Progression rate (rapid, slow, variable)
  • Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  • Disease duration (self-limited, chronic lifelong)

    Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM

  • Patterns:
  • Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
  • Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

  • Epidemiology:
  • Prevalence (cases per 100,000 at given time)
  • Incidence (new cases per 100,000 per year)

    Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries

  • For Genetic Etiology:
  • Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  • Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
  • Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
  • Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
  • Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
  • Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
  • Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
  • Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
  • Population Demographics:
  • Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  • Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  • Geographic distribution of specific variants
  • Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
  • Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

  • Clinical Tests:
  • Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
  • Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  • Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
  • Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
  • Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
  • Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
  • Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
  • Genetic Testing:

    Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen

  • Overview of recommended genetic testing approach
  • Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
  • Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
  • Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
  • Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
  • Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
  • Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
  • FISH > Search first: ClinVar, cytogenetics databases, PubMed
  • Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
  • Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
  • Omics-Based Diagnostics (if applicable):
  • RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
  • Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
  • Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
  • Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
  • Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
  • Clinical Criteria:
  • Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
  • Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
  • Screening:
  • Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

  • Survival and Mortality:
  • Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
  • Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
  • Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
  • Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
  • Morbidity and Function:
  • Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
  • Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
  • Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
  • Disease Course:
  • Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
  • Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
  • Prediction:
  • Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
  • Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

  • Pharmacotherapy:
  • Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  • Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
  • Advanced Therapeutics:
  • Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  • Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
  • RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
  • Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  • Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
  • Surgical and Interventional:
  • Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
  • Supportive and Rehabilitative:
  • Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
  • Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
  • Experimental:
  • Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
  • Treatment Outcomes:
  • Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
  • Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
  • Treatment Strategy:
  • Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
  • Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
  • Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.

13. Prevention

  • Prevention Levels:
  • Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
  • Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
  • Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
  • Immunization: Vaccine strategies (if applicable)

    Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database

  • Screening and Early Detection:
  • Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
  • Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
  • Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
  • Behavioral Interventions: Lifestyle modifications to reduce risk

    Search first: CDC, WHO, behavioral intervention databases, Cochrane Library

  • Counseling: Genetic counseling (risk assessment, family planning guidance)

    Search first: NSGC resources, ACMG guidelines, GeneReviews

  • Public Health:
  • Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
  • Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
  • Prophylaxis: Preventive medications or procedures

    Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

  • Taxonomy: Species affected (with NCBI Taxon identifiers)

    Search first: NCBI Taxonomy

  • Breed: Specific breeds affected (with VBO identifiers if applicable)

    Search first: VBO (Vertebrate Breed Ontology)

  • Gene: Orthologous genes in other species (with NCBI Gene IDs)

    Search first: NCBI Gene

  • Natural Disease:
  • Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  • Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
  • Comparative Biology:
  • Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
  • Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
  • Transmission (if applicable):
  • Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
  • Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

  • Model Types:
  • Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
  • Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  • Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
  • Genetic Models:
  • Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
  • Model Characteristics:
  • Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
  • Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
  • Applications:
  • Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
  • Resources:
  • Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

  • Cite primary literature (PMID preferred) for all mechanistic and clinical claims
  • Prioritize recent reviews and landmark papers
  • Include direct quotes from abstracts where possible to support key statements
  • Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Warning: no contexts were retrieved, so this answer is not grounded in evidence but is instead a direct response from the agent model.

PAX3 Waardenburg Spectrum: retrieval-limited report

In this session, the available literature tools returned no citable evidence contexts, consistent with a temporary retrieval outage.

Because of that limitation, a properly cited report with PMIDs, URLs, publication dates, abstract quotes, and evidence-backed statistics could not be produced.

The disease concept intended here is likely PAX3-associated Waardenburg syndrome, especially Waardenburg syndrome type 1 (WS1) and type 3 / Klein-Waardenburg syndrome (WS3).

Unsourced scaffold summary: - Likely causal gene: PAX3. - Likely inheritance: autosomal dominant with variable expressivity. - Core draft phenotypes: sensorineural hearing loss, pigmentary abnormalities of iris/hair/skin, dystopia canthorum or telecanthus-related facial spacing changes, and upper-limb anomalies in WS3. - Draft mechanism: developmental transcription-factor dysfunction affecting neural crest / melanocyte biology and related craniofacial and auditory development. - Draft anatomy: inner ear/cochlea, iris, skin, hair follicles, craniofacial structures, and upper limb in WS3. - Draft management: audiology, hearing aids or cochlear implant evaluation when indicated, speech-language support, ophthalmic/orthopedic assessment as needed, and genetic counseling.

Retrieval plan summary: - Query GeneReviews: Waardenburg syndrome PAX3 GeneReviews. - Query OMIM: PAX3 Waardenburg syndrome type 1 OMIM and PAX3 Waardenburg syndrome type 3 OMIM. - Query Orphanet: Orphanet Waardenburg syndrome type 1 PAX3. - Query ClinVar / ClinGen / gnomAD for variant interpretation and frequency. - Query PubMed with 2023-2024 priority: PAX3 Waardenburg syndrome 2023, PAX3 Waardenburg syndrome 2024, Waardenburg syndrome type 1 PAX3 review, Klein-Waardenburg PAX3. - Query HPO, DECIPHER, MGI, and ZFIN for phenotype, structural-variant, and model-organism evidence.

This scaffold should be treated only as a drafting aid and replaced with a fully cited report once source retrieval is functioning again.

Blockquote: This blockquote provides a concise user-facing notice that literature retrieval failed in the current session, preventing a properly cited report. It also summarizes the provisional unsourced disease scaffold and the highest-priority follow-up searches needed to complete a fully cited PAX3 Waardenburg spectrum review.

Artifacts